Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1999 1
2001 2
2006 1
2007 1
2008 1
2009 1
2013 3
2016 3
2017 1
2018 1
2020 2
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Spinophilin expression in postmortem prefrontal cortex of schizophrenic subjects: Effects of antipsychotic treatment.
Brocos-Mosquera I, Gabilondo AM, Meana JJ, Callado LF, Erdozain AM. Brocos-Mosquera I, et al. Eur Neuropsychopharmacol. 2021 Jan;42:12-21. doi: 10.1016/j.euroneuro.2020.11.011. Epub 2020 Nov 27. Eur Neuropsychopharmacol. 2021. PMID: 33257116
In the present study spinophilin protein expression was determined by western blot in the postmortem dorsolateral prefrontal cortex of 24 subjects with schizophrenia (12 antipsychotic-free and 12 antipsychotic-treated subjects) and 24 matched controls. ...
In the present study spinophilin protein expression was determined by western blot in the postmortem dorsolateral prefrontal cortex of 24 su …
Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study.
Correll CU, Cucchiaro J, Silva R, Hsu J, Pikalov A, Loebel A. Correll CU, et al. CNS Spectr. 2016 Oct;21(5):393-402. doi: 10.1017/S1092852915000917. Epub 2016 Apr 6. CNS Spectr. 2016. PMID: 27048911
METHODS: Patients who completed a 6-week, double-blind (DB), placebo-controlled trial continued in a 22-month, open-label (OL) study during which they received once-daily, flexible-doses of lurasidone, 40-120 mg. ...Thirty-seven patients (14.7%) discontinued due to an adve …
METHODS: Patients who completed a 6-week, double-blind (DB), placebo-controlled trial continued in a 22-month, open-label (OL) study …
Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment).
Nakamura T, Kubota T, Iwakaji A, Imada M, Kapás M, Morio Y. Nakamura T, et al. Drug Des Devel Ther. 2016 Jan 14;10:327-38. doi: 10.2147/DDDT.S95100. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 26834462 Free PMC article. Clinical Trial.
Pharmacokinetics of cariprazine and the two clinically relevant metabolites (desmethyl- and didesmethyl-cariprazine) was evaluated in a clinical pharmacology study. METHODS: This was a multicenter, randomized, open-label, parallel-group, fixed-dose (3, 6, or 9 mg/da …
Pharmacokinetics of cariprazine and the two clinically relevant metabolites (desmethyl- and didesmethyl-cariprazine) was evaluated in a c …
Clinical effectiveness of metacognitive training as a transdiagnostic program in routine clinical settings: A prospective, multicenter, single-group study.
Tanoue H, Yoshinaga N, Hayashi Y, Ishikawa R, Ishigaki T, Ishida Y. Tanoue H, et al. Jpn J Nurs Sci. 2021 Apr;18(2):e12389. doi: 10.1111/jjns.12389. Epub 2020 Nov 11. Jpn J Nurs Sci. 2021. PMID: 33174673 Clinical Trial.
AIM: To evaluate the clinical effectiveness of metacognitive training (MCT) as a transdiagnostic program, on a diverse population with mental disorders in routine Japanese day-care settings. ...RESULTS: Thirty-four participants enrolled in the study and received MCT (schiz …
AIM: To evaluate the clinical effectiveness of metacognitive training (MCT) as a transdiagnostic program, on a diverse population wit …
Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS()) in the Swedish COAST-study.
Brain C, Allerby K, Sameby B, Quinlan P, Joas E, Karilampi U, Lindström E, Eberhard J, Burns T, Waern M. Brain C, et al. Eur Neuropsychopharmacol. 2013 Dec;23(12):1754-62. doi: 10.1016/j.euroneuro.2013.09.001. Epub 2013 Sep 19. Eur Neuropsychopharmacol. 2013. PMID: 24091164
The aim was to investigate clinical predictors of adherence to antipsychotics. Medication use was electronically monitored with a Medication Event Monitoring System (MEMS()) for 12 months in 112 outpatients with schizophrenia and schizophrenia-like psychosis according to D …
The aim was to investigate clinical predictors of adherence to antipsychotics. Medication use was electronically monitored with a Med …
Nicotine enhances antisaccade performance in schizophrenia patients and healthy controls.
Petrovsky N, Ettinger U, Quednow BB, Landsberg MW, Drees J, Lennertz L, Frommann I, Heilmann K, Sträter B, Kessler H, Dahmen N, Mössner R, Maier W, Wagner M. Petrovsky N, et al. Int J Neuropsychopharmacol. 2013 Aug;16(7):1473-81. doi: 10.1017/S1461145713000011. Epub 2013 Feb 11. Int J Neuropsychopharmacol. 2013. PMID: 23399382 Free article. Clinical Trial.
We hypothesized that, if nicotine is a genuine cognitive enhancer, its administration would improve antisaccade performance both in smoking and non-smoking participants. A total of 22 patients with schizophrenia (12 smokers and 10 non-smokers) and 26 controls (14 sm …
We hypothesized that, if nicotine is a genuine cognitive enhancer, its administration would improve antisaccade performance both in smoking …
Small intestine permeability in schizophrenia.
Lambert MT, Bjarnason I, Connelly J, Crow TJ, Johnstone EC, Peters TJ, Smethurst P. Lambert MT, et al. Br J Psychiatry. 1989 Nov;155:619-22. doi: 10.1192/s0007125000018092. Br J Psychiatry. 1989. PMID: 2514959
Gastrointestinal permeability was assessed by means of absorption of 51Cr-labelled EDTA in 24 patients with schizophrenia (12 in relapse and 12 in remission). The results were compared with those for patients with coeliac disease and those for normal controls. ...
Gastrointestinal permeability was assessed by means of absorption of 51Cr-labelled EDTA in 24 patients with schizophrenia (12 …
Durability of the effects of cognitive-behavioural therapy in the treatment of chronic schizophrenia: 12-month follow-up.
Tarrier N, Wittkowski A, Kinney C, McCarthy E, Morris J, Humphreys L. Tarrier N, et al. Br J Psychiatry. 1999 Jun;174:500-4. doi: 10.1192/bjp.174.6.500. Br J Psychiatry. 1999. PMID: 10616627 Clinical Trial.
AIMS: To evaluate the durability of the treatment effects of cognitive-behavioural therapy for chronic schizophrenia one year after treatment termination. METHOD: A comparison of clinical outcomes was made at one-year follow-up from a randomised trial of cogn …
AIMS: To evaluate the durability of the treatment effects of cognitive-behavioural therapy for chronic schizophrenia one year after treatmen …
Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study.
Zhang Y, Fang X, Fan W, Tang W, Cai J, Song L, Zhang C. Zhang Y, et al. Psychopharmacology (Berl). 2018 Apr;235(4):1191-1198. doi: 10.1007/s00213-018-4835-6. Epub 2018 Feb 1. Psychopharmacology (Berl). 2018. PMID: 29392373
OBJECTIVES: In this study, we performed a prospective, open-label, 12-week observation trial to investigate whether peripheral BDNF may represent a potential biomarker for the effect of cognitive improvement induced by olanzapine in patients with schizophrenia. ...Addition …
OBJECTIVES: In this study, we performed a prospective, open-label, 12-week observation trial to investigate whether peripheral BDNF m …
Adjunctive selective estrogen receptor modulator increases neural activity in the hippocampus and inferior frontal gyrus during emotional face recognition in schizophrenia.
Ji E, Weickert CS, Lenroot R, Kindler J, Skilleter AJ, Vercammen A, White C, Gur RE, Weickert TW. Ji E, et al. Transl Psychiatry. 2016 May 3;6(5):e795. doi: 10.1038/tp.2016.59. Transl Psychiatry. 2016. PMID: 27138794 Free PMC article. Clinical Trial.
The present study was designed to determine the extent to which adjunctive raloxifene treatment would alter abnormal neural activity during angry facial emotion recognition in schizophrenia. Twenty people with schizophrenia (12 men, 8 women) participated in a 13-wee …
The present study was designed to determine the extent to which adjunctive raloxifene treatment would alter abnormal neural activity during …
17 results